A new oncology joint venture has been set up in the UK to exploit the gene editing capabilities of Horizon Discovery Group Plc and aptamer technology developed in the US and owned by Centauri Therapeutics Ltd, a UK anti-infectives company. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
